Immunovant, Inc.
NASDAQ:IMVTBiotechnology
+$0.69 today
- Market cap
- $6.73B
- Beta
- 0.79
- P/E (TTM)
- -14.3
- EPS (TTM)
- -$2.48
Volume 0.73M
Average 1.84M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Immunovant, Inc.
NASDAQ:IMVT
Intrinsic Alpha fair value
Locked
Current Price
$32.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
TG Therapeutics, Inc. NASDAQ:TGTX | $9.75B | $64.51 | Undervalued | 16.4 | +113.07% |
First Tracks Biotherapeutics Inc NASDAQ:TRAX | $1.98B | $47.10 | Not rated | -6.1 | — |
Zenas BioPharma, Inc. NASDAQ:ZBIO | $1.90B | $28.01 | Not rated | -2.5 | -28.13% |
AnaptysBio, Inc. NASDAQ:ANAB | $1.38B | $46.25 | Overvalued | -59.7 | +88.77% |
Cullinan Therapeutics, Inc. NASDAQ:CGEM | $667.39M | $10.28 | Not rated | -4.0 | +4.01% |
Annexon, Inc. NASDAQ:ANNX | $642.26M | $3.92 | Not rated | -4.8 | -20.14% |
Aclaris Therapeutics, Inc. NASDAQ:ACRS | $621.76M | $3.92 | Not rated | -8.2 | +45.23% |
Cabaletta Bio, Inc. NASDAQ:CABA | $276.12M | $1.28 | Not rated | -1.8 | -53.02% |
Q32 Bio Inc. NASDAQ:QTTB | $260.64M | $8.71 | Not rated | 5.4 | +339.38% |
Immunic, Inc. NASDAQ:IMUX | $102.61M | $7.52 | Not rated | -4.1 | +7.41% |
Continue the stock analysis
Jump to another research area for this company.